Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trialSanjay Ramakrishnan, Mona Bafadhel, Philippa C. Matthews et al.|The Lancet Respiratory Medicine|2021Cited by 434
Oxidative stress dependent microRNA-34a activation via PI3Kα reduces the expression of sirtuin-1 and sirtuin-6 in epithelial cellsJonathan Baker, Peter J. Barnes|Scientific Reports|2016Cited by 171
Early Th2 inflammation in the upper respiratory mucosa as a predictor of severe COVID-19 and modulation by early treatment with inhaled corticosteroids: a mechanistic analysisJonathan Baker, Mona Bafadhel, Mahdi Mahdi et al.|The Lancet Respiratory Medicine|2022Cited by 58
Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trialSanjay Ramakrishnan, Mona Bafadhel, Dan V. Nicolau et al.|medRxiv|2021Cited by 25
Senolytic therapy reduces inflammation in epithelial cells from COPD patients and in smoke-exposure miceJonathan Baker, Kazuhiro Ito|Frontiers in Medicine|2025Cited by 9